Briefcases -- All Litigations -- ACTEMRA INVESTIGATION BY Mass Tort Nexus (tocilizumab) from Genentech (Roche) Re: Rheumetoid Arthritis Drug (FDA Approval October 2008)

ACTEMRA INVESTIGATION BY Mass Tort Nexus (tocilizumab) from Genentech (Roche) Re: Rheumetoid Arthritis Drug (FDA Approval October 2008)

Case Files
News
Committees
Request a Document

Categories

Sort by:
  1. ACTEMRA (tocilizumab): FDA and EU Analysis, Studies and Research 1 of 2 Re: Genentech (Roche) - Rheumatoid Arthritis FDA Drug Approval October 2008
  2. ACTEMRA (tocilizumab): FDA and EU Analysis, Studies and Research 2 of 2 Re: Genentech (Roche) - Rheumatoid Arthritis FDA Drug Approval October 2008
  3. ACTEMRA (tocilizumab) by Genentech (Roche) Re: Rheumatoid Arthritis FDA Drug Approval October 2008
    1. ACTEMRA (tocilizumab) Evidentiary Documents

Documents

Sort by:
  1. 2008-4371b1-01-FDA Meeting Summary 2008.pdf
  2. Ablynx: Study of Nanobodies by Flanders Institute Science Faculty - Pharmaceuticals and Biotechnologies (2013)
  3. Australian Public Assessment Report for tocilizumab (rch) Proprietary Product Name: Actemra Sponsor: Roche Products Pty Ltd
  4. Actemra FDA Clinical Pharmacology Reviews.pdf
  5. Acterma FDA Label Change March 2017.pdf
  6. fig1_10.1002%2Fart.23940.pptx
  7. fig4_10.1002%2Fart.23940.pptx
  8. ROCHE: A Strategic Business Analysis in Powerpoint
  9. Current Developments in U.S. Patent Law: Fordham IP Institute by Dimitrios T. Drivas April 24, 2014
  10. Actemra FDA Microbiology Reviews.pdf
  11. Acterma FDA Label Change May 2017.pdf
  12. Acterma FDA Label May 2013.pdf
  13. Acterma FDA Label October 2012.pdf
  14. Acterma FDA Supplemental Approval 2017.pdf
  15. Treatment options in patients with rheumatoid arthritis failing.pdf
  16. Ablynx: Study Part II of Nanobodies by Flanders Institute Science Faculty - Pharmaceuticals and Biotechnologies (2013)
  17. Comaprative Study Re: Abbott and Roche in Powerpoint by Mr Amin Rajani
  18. Coventry Health Care of Missouri Insurance Coverage Analysis March 25, 2014 in Powerpoint
  19. fig2_10.1002%2Fart.23940.pptx
  20. fig3_10.1002%2Fart.23940.pptx
  21. Rheumatoid Arthritis World Map Deaths Per Million Persons by World Health Organization 2012
  22. Stidham_IBD-Update-Talk-Final.pptx
  23. T1_Results_Slideset_3_4_15.pptx
  24. the-role-of-tocilizumab-monotherapy-in-the-management-of-rheumatoid-arthritis-a-review.pdf
  25. Tocilizumab and tofacitinib increase lipids in RA patients _ Rheumatology News.pdf
  26. Tocilizumab in rheumatoid arthritis A case study of safety evaluations.pdf
  27. tocilizumab__RoActemra__FINAL_July_2014_for_website.pdf
  28. Tocilizumab_2017_updatedDSedits_170220 (1).pdf
  29. Tocilizumab_2017_updatedDSedits_170220.pdf
  30. Tocilizumab Protocol FRI June 19, 2015
  31. Tocilizumabinterim_monograph_16June2010_formatted.pdf
  32. Actemra EU Med Agency Giant Cell.pdf
  33. Actemra FDA Chemistry Reviews.pdf
  34. Actemra FDA Approval Letter for Oct 2013 Label.pdf
  35. Actemra FDA Enviromental Reviews.pdf
  36. Actemra FDA General Reviews.pdf
  37. Actemra FDA Label Revised May 2017.pdf
  38. Actemra FDA Label Update Oct 2013.pdf
  39. Actemra FDA Other Reviews.pdf
  40. Actemra FDA Pharmcological Reviews.pdf
  41. Actemra FDA Prop Name Reviews.pdf
  42. Actemra FDA Risk Assessment Reviews.pdf
  43. Actemra FDA Statistical Reviews.pdf
  44. Actemra FDA Summary Review for Oct 2013 Label.pdf
  45. Actemra TGA Austrailia.pdf
  46. Acterma FDA Labeling-Medication Guide 2017.pdf
  47. Acterma FDA Label Change September 2013.pdf
  48. Acterma FDA Efficacy-Labeling Change With Clinical Data September 2016.pdf
  49. Acterma FDA Label April 2011 Supplement.pdf
  50. Acterma FDA Label April 2011.pdf
  51. Acterma FDA Label April 2013.pdf
  52. Acterma FDA Label August 2012.pdf
  53. Acterma FDA Label Jan 2010.pdf
  54. Acterma FDA Label Jan 2011 Supplement 2.pdf
  55. Acterma FDA Label Jan 2011 Supplement.pdf
  56. Acterma FDA Label January 2011.pdf
  57. Acterma FDA Label March 2017.pdf
  58. Acterma FDA Label October 2013.pdf
  59. Acterma FDA Label October 2016.pdf
  60. Acterma FDA REMS Changes August 2015.pdf
  61. Acterma Initial FDA Approval Letter January 8 2010.pdf
  62. Acterma Initial FDA Label 2010.pdf
  63. DHCP Letter Canada.pdf
  64. Tocilizumab raises cholesterol, but not cardiovascular events _ Rheumatology News.pdf
  65. Tocilizumab raises cholesterol, but not cardiovascular events _ Rheumatology News.pdf
  66. fig5_10.1002%2Fart.23940.pptx
  67. Rheumatoid_arthritis_world_map-Deaths_per_million_persons-WHO2012.svg.png
  68. ROCHE: A Strategic Business Analysis in Powerpoint
View All